Duration of Use of Highly Effective Reversible Contraception
Real-world Duration of Use for Highly Effective Reversible Contraception (HERC): A Retrospective Review
1 other identifier
observational
13,880
1 country
1
Brief Summary
To assess the proportion of women who use HERC for ≥2 years of duration
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2015
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2015
CompletedFirst Submitted
Initial submission to the registry
April 8, 2015
CompletedFirst Posted
Study publicly available on registry
April 13, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 28, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
March 28, 2016
CompletedMarch 16, 2017
March 1, 2017
12 months
April 8, 2015
March 14, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Proportion of women who use HERC
2 years post-HERC initiation
Secondary Outcomes (1)
Duration of real world use of three different HERC devices
2 years post-HERC initiation
Other Outcomes (3)
Difference in patient characteristics of women who chose different HERC devices
2 years post-HERC initiation
Proportion of HERC used for ≥3 years of duration
≥3 years post-HERC initiation
Model the predictors of ≥3 years of duration
≥3 years post-HERC initiation
Study Arms (1)
HERC
Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)
Interventions
Levonorgestrel-releasing intrauterine device 20 mcg/day
Eligibility Criteria
Women who had an IUD or contraceptive implant inserted at the University of Utah healthcare system
You may qualify if:
- Women who had an IUD or contraceptive implant inserted and removed within the University of Utah from January 1, 2004 to October 31, 2012
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bayerlead
- University of Utahcollaborator
Study Sites (1)
Unknown Facility
Salt Lake City, Utah, United States
Related Publications (3)
Sanders J, Turok D, Gawron L, Law A, Wen L, Lynen R. Continuation of Long-Acting Reversible Contraception at Two Years in a University Healthcare Setting: A Retrospective Review. JMCP 2016;22(4a):S126
BACKGROUNDSanders JN, Turok DK, Gawron LM, Law A, Wen L, Lynen R. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review. Am J Obstet Gynecol. 2017 Jun;216(6):590.e1-590.e8. doi: 10.1016/j.ajog.2017.02.003. Epub 2017 Feb 8.
PMID: 28188772RESULTSanders J, Turok D, Gawron L, Law A, Wen L, Lynen R. Three-Year Continuation of Long-Acting Reversible Contraceptive methods in a Mixed-Payer Health Care Setting: A Retrospective Review. Contraception 2016;94:405-406.
RESULT
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bayer Study Director
Bayer
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 8, 2015
First Posted
April 13, 2015
Study Start
April 1, 2015
Primary Completion
March 28, 2016
Study Completion
March 28, 2016
Last Updated
March 16, 2017
Record last verified: 2017-03